查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2018837

生物医学植入市场：按类型、材料和应用划分－2026-2032年全球市场预测

Biological Implants Market by Type, Material, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，生物植入市场价值将达到 499.1 亿美元，到 2026 年将成长到 609.1 亿美元，到 2032 年将达到 2003.9 亿美元，复合年增长率为 21.96%。

主要市场统计数据
基准年 2025 499.1亿美元
预计年份：2026年 609.1亿美元
预测年份 2032 2003.9亿美元
复合年增长率 (%) 21.96%

本概述考察了生物医学植入的现状，重点关注决定其普及和长期永续性的临床、技术和营运驱动因素。

植入领域融合了前沿材料科学、外科创新和不断发展的法律规范，为医疗保健相关人员带来了机会和挑战。生物材料、微型电子装置和植入式药物传输系统的快速发展拓展了治疗应用范围，同时也引发了人们对长期性能、生物相容性和临床证据生成等方面的疑问。在临床实践中，多学科团队正在重新定义整形外科、循环系统医学、牙科、神经科、眼科和脊椎医学等领域的治疗流程，这要求制定综合产品策略，以兼顾手术流程、患者报告结果和支付方趋势。

个人化、数位化增强、程序创新和监管加强如何重塑产品开发、临床引入和供应策略。

由于技术、临床和政策因素的融合，植入式医疗技术领域正经历着变革性的转变。首先，材料科学和製造技术的进步使得患者个体化植入和模组化平台成为可能，从而应对解剖结构的多样性和疾病进展，将个人化从概念转变为实践。其次，微创和影像导引手术正在拓展适应症并缩短恢復时间，使价值主张从单纯的设备成本转向整个治疗过程中的疗效。第三，透过植入感测器、远端监测和预测分析实现的数位化增强，能够进行持续的性能评估和早期疗育，从而将上市后监管框架从定期检查转变为即时管理。

评估 2025 年美国关税措施对零件采购、製造地和采购实务的营运和策略影响。

美国2025年实施的关税政策为植入式医疗设备的製造商、供应商和经销商带来了一系列复杂的考量，影响直接采购成本和更广泛的供应链决策。在零件层面，某些进口原料关税的提高给依赖海外采购的特殊合金、电子元件和成品模组的医疗设备带来了价格上涨压力。为此，许多供应商迅速启动了成本透明化计划，并与供应商重新谈判合约条款，以保护利润率并维持临床试验点的供应。同时，一些製造商加快了对替代供应商的认证，并扩大了关键零件的在地采购，以降低贸易政策变化带来的风险。

細項分析突显了从整形外科到眼科植入物等不同植入类别的开发、监管和商业化策略的差异。

对植入分类的详细分析揭示了不同的创新路径、监管考虑和临床应用模式，这些都需要在产品开发和商业化方面采取个人化的策略。整形外科植入类别包括关节重建、骨合成和创伤固定。关节重建又细分为髋关节置换、膝关节置换和肩关节置换，每种关节置换都有其独特的手术流程和植入生命週期考量。骨合成分为骨板和骨螺钉，创伤固定则涵盖外固定器、髓内钉以及钢板和螺钉，每个子类别都指明了特定的材料和机械性能要求，这些要求会影响研发重点。

全球主要地区在管理体制、报销结构和资本投资方面的差异如何影响临床导入和商业化选择？

区域趋势持续影响着製造商和医疗保健系统的优先事项，不同地理市场的监管、报销和临床应用模式也各不相同。在美洲，临床实务高度重视实证创新和流程效率，支付方也越来越要求提供可验证的疗效和真实世界的临床绩效指标作为报销依据。在该地区运营的製造商优先投资于完善的上市后监测系统、与综合医疗保健网络建立合作关係以及开展临床医生培训，以在註重成本的环境下促进产品应用。

跨国公司的规模与Start-Ups的专业创新相互交汇，形成竞争环境：伙伴关係、平台策略和有针对性的临床差异化。

植入医疗器材领域的竞争格局涵盖了从成熟的跨国医疗设备製造商到敏捷的临床阶段Start-Ups，形成了一个充满活力的环境，规模、监管专业知识和专业创新都至关重要。大型公司继续利用其广泛的产品系列、强大的临床网路和完善的品管系统来支援复杂的销售週期和全球监管申报。这些公司优先考虑生命週期管理、模组化平台策略以及旨在拓展临床适应症和整合数位医疗能力的策略伙伴关係关係。

公司应实施切实可行的策略和营运措施，以增强韧性，加快在临床环境中的采用，并确保与监管机构和支付方的合作。

产业领导者必须将洞察转化为可执行的步骤，以增强韧性、加速部署并保障病患安全，同时保持商业性可行性。首先，绘製关键供应链节点图，核实高风险组件二级供应商的合格，并实施透明的成本和前置作业时间管理系统，以降低政策变更和物流中断带来的风险。其次，透过设计可操作的临床试验和真实世界数据 (RWE) 项目，投资产生符合支付方终点的临床证据，以证明功能性结果、再入院率和长期设备性能的改善。第三，在产品设计中优先考虑模组化和可升级性，以扩大临床有效性并实现迭代改进，而无需完全更换。

整合临床、监管、供应链和从业人员视角的研究途径，确保了全面且检验的知识。

本分析的基础研究结合了对监管文件、同行评审的临床文献、专利和公开医疗设备註册资讯的系统性审查，以及来自临床医生、采购经理、监管专家和生产企业高管的针对性专家见解。主要活动包括与多学科执业外科医生、医疗设备製造商的品质和监管负责人以及负责植入物流的供应链经理进行结构化访谈和研讨会。次要研究涉及对每种医疗设备的临床试验註册数据、监管指导文件和上市后监测总结的分析，以全面了解其安全性和性能趋势。

透过整合将医疗设备创新、证据产生和营运韧性连结起来的策略重点，我们能够带来可持续的临床和系统效益。

生物医学植入正进入一个技术多样性和系统层面考量决定最终产品优劣和患者获益的关键阶段。个人化材料、数位化监测和手术创新技术的融合，正在重新定义价值，使其从以设备为中心的特性转向以综合护理结果为导向的治疗。协调平台设计、临床证据策略和自适应製造的机构，不仅能够更有效地应对当前的政策和采购压力，还能透过显着改善患者功能和提升护理效率，为永续应用开闢新途径。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：生物医学植入市场：按类型划分

  • 自体移植
  • 同种异体移植
  • 异质骨移植

第九章：生物医学植入市场：依材料分类

  • 胶原蛋白蛋白
  • 聚合物材料
  • 组织起源
  • 混合/生物复合材料

第十章：生物医学植入市场：依应用领域划分

  • 整形外科植入
  • 心血管植入
  • 植入
  • 颅颜和颚颜面植入

第十一章：生物医学植入市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章：生物医学植入市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章：生物医学植入市场：按国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章：美国生物医学植入市场

第十五章：中国生物医学植入市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Alphatec Spine, Inc.
  • Auto Tissue Berlin GmbH
  • Baxter International, Inc.
  • Becton, Dickinson and Company
  • BioPolymer GmbH & Co. KG
  • Boston Scientific Corporation
  • Citagenix Inc.
  • Conmed Corporation
  • CryoLife, Inc.
  • Edwards Lifesciences Corporation
  • Globus Medical, Inc.
  • Integra LifeSciences Corporation
  • Johnson & Johnson
  • Medical Device Business Services, Inc.
  • Medtronic plc
  • RTI Surgical, Inc.
  • Sanara MedTech, Inc.
  • Smith & Nephew plc
  • Stryker Corporation
  • Surgenex LLC
  • TissueTech, Inc.
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-ED54C46E8D5E

The Biological Implants Market was valued at USD 49.91 billion in 2025 and is projected to grow to USD 60.91 billion in 2026, with a CAGR of 21.96%, reaching USD 200.39 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 49.91 billion
Estimated Year [2026] USD 60.91 billion
Forecast Year [2032] USD 200.39 billion
CAGR (%) 21.96%

Framing the contemporary biological implants landscape with clinical, technological, and operational drivers that determine adoption and long-term viability

The field of biological implants sits at the intersection of advanced materials science, surgical innovation, and evolving regulatory oversight, creating both opportunity and complexity for healthcare stakeholders. Rapid advances in biomaterials, miniaturized electronics, and implantable drug delivery are extending therapeutic reach while simultaneously raising questions around long-term performance, biocompatibility, and clinical evidence generation. At the clinical interface, multidisciplinary teams are redefining treatment algorithms across orthopedics, cardiovascular care, dentistry, neurology, ophthalmology, and spinal medicine, demanding integrated product strategies that account for procedural workflow, patient-reported outcomes, and payer dynamics.

Operationally, manufacturers and providers are navigating tighter supply chain expectations, heightened scrutiny over post-market surveillance, and rising expectations for cybersecurity in connected devices. Technological convergence-where sensors, AI-driven diagnostics, and adaptive stimulation meet established implant platforms-is accelerating the pace of innovation but also requiring deeper cross-functional collaboration. As early adopters demonstrate clinical and economic value, procurement, clinical, and regulatory stakeholders must coordinate to translate device-level advances into scalable care pathways that prioritize safety, reimbursement viability, and equitable patient access.

How personalization, digital augmentation, procedural innovation, and regulatory tightening are reshaping product development, clinical adoption, and supply strategies

The landscape for implantable medical technologies is undergoing transformative shifts driven by converging technological, clinical, and policy forces. First, personalization is moving from concept to practice as materials science and manufacturing advances enable patient-specific implants and modular platforms that accommodate anatomical variability and evolving disease presentations. Second, minimally invasive and image-guided procedures are expanding indications and shortening recovery times, shifting value conversations from device cost alone to total episode-of-care outcomes. Third, digital augmentation-through sensors embedded in implants, remote monitoring, and predictive analytics-enables continuous performance assessment and earlier interventions, thereby reframing post-market surveillance from periodic checks to real-time stewardship.

In parallel, regulatory frameworks are adapting to these changes by emphasizing robust clinical evidence, lifecycle management, and cybersecurity controls for networked devices. Supply chains are also recalibrating; providers and manufacturers are balancing globalization with the need for onshore capabilities to ensure continuity of critical components. These shifts are influencing investment priorities, where capital increasingly favors platforms that offer interoperable ecosystems, modular upgrades, and demonstrable improvements in patient-centered outcomes. Consequently, organizations that integrate clinical insight, regulatory foresight, and manufacturing flexibility will be best positioned to capture clinical trust and operational resilience.

Assessing the operational and strategic consequences of the 2025 United States tariff measures on component sourcing, manufacturing footprints, and procurement behaviors

The tariff environment in the United States introduced in 2025 has created a complex set of considerations for manufacturers, providers, and distributors of implantable devices, affecting both direct procurement costs and broader supply chain decisions. At the component level, duties on certain imported inputs have increased the price pressure for devices that rely on specialized alloys, electronic components, and finished modules sourced overseas. In response, many suppliers initiated rapid cost-transparency programs and renegotiated supplier terms to protect margin and preserve clinical access. Simultaneously, some manufacturers accelerated qualifications of alternative suppliers and increased local sourcing for critical components to reduce exposure to trade policy volatility.

Beyond direct cost impacts, the tariff stance influenced strategic choices around manufacturing footprint and inventory posture. Several organizations revisited localization strategies, evaluating near-shore and onshore manufacturing investments to mitigate future policy risk and shorten replenishment lead times. These investments often required parallel adjustments to quality systems, regulatory filings, and workforce training, creating near-term implementation challenges but improving operational resilience long term. Clinicians and procurement teams observed that pricing dynamics prompted more stringent value assessments and extended contract negotiations, encouraging stronger collaboration between clinical evidence teams and commercial functions to preserve access while maintaining sustainable business models.

Segment-specific analysis highlighting how implant subcategories from orthopedics to ocular devices demand distinct development, regulatory, and commercialization strategies

A nuanced segmentation of implant classes reveals differentiated innovation pathways, regulatory considerations, and clinical adoption patterns that demand tailored strategies for product development and commercialization. The orthopedic implant category encompasses joint replacement, osteosynthesis, and trauma fixation; joint replacement further differentiates into hip, knee, and shoulder replacement subdomains, each with distinct surgical workflows and implant lifecycle considerations. Osteosynthesis divides into bone plates and bone screws, while trauma fixation spans external fixators, intramedullary nails, and plates and screws, with each subcategory exhibiting specific material and mechanical performance requirements that influence R&D priorities.

Cardiovascular implants include heart valves, stents, and vascular grafts; heart valves are split between mechanical and tissue options, and stents are categorized as bare metal or drug-eluting, with divergent regulatory paths and evidence expectations. Dental implants are reviewed across endosseous, subperiosteal, and zygomatic implants; endosseous implants further separate into blade form and root form, each addressing different anatomical constraints and restoration philosophies. Spinal implants cover disc replacement, spinal fixation, and spinal fusion devices; spinal fixation is further detailed as plates and screws and rods, while spinal fusion devices include bone graft substitutes and cages, signaling varied biological integration and device-host interactions. Neurological implants span deep brain stimulators, spinal cord stimulators, and vagal nerve stimulators; deep brain stimulators are examined in adaptive and fixed-rate formats, and spinal cord stimulators in paddle and percutaneous configurations, reflecting differences in precision therapy and implantation complexity. Ocular implants concentrate on intraocular lenses and retinal implants; intraocular lenses are profiled as monofocal, multifocal, and toric, and retinal implants as epiretinal and subretinal, each demanding specialized surgical techniques and patient selection criteria.

Understanding these segment-specific nuances enables tailored clinical development plans and targeted reimbursement strategies. For example, modular platforms and upgrade paths are more relevant in joint replacement and spinal systems, whereas miniaturization and power management are central to neurological and retinal implants. Regulatory submission strategies, post-market evidence generation, and clinician training programs must align with the mechanical, biological, and procedural characteristics unique to each segmentation node to optimize adoption and long-term safety outcomes.

How divergent regulatory regimes, reimbursement frameworks, and capacity investments across major global regions influence clinical adoption and commercialization choices

Regional dynamics continue to drive differentiated priorities for manufacturers and health systems, with geographic markets exhibiting distinct regulatory, reimbursement, and clinical adoption patterns. In the Americas, clinical practice strongly favors evidence-backed innovations and procedural efficiency, and payers increasingly condition reimbursement on demonstrable outcomes and real-world performance metrics. Manufacturers operating in this region prioritize robust post-market surveillance systems, partnerships with integrated delivery networks, and investments in clinician education to support uptake in cost-conscious environments.

Across Europe, Middle East & Africa, regulatory harmonization and cross-border approvals influence go-to-market sequencing and clinical trial design, while diverse payer models require adaptable pricing and access strategies. The region presents a mixture of centralized procurement programs in some jurisdictions and highly decentralized hospital purchasing in others, so manufacturers must balance standardized value dossiers with localized value arguments. In the Asia-Pacific region, rapid technology adoption is coupled with varied regulatory maturity and an emphasis on scalable manufacturing and cost competitiveness. Several markets in this region are investing heavily in domestic capacity building and local clinical evidence generation, which creates both collaboration opportunities and competitive pressures for global firms that seek to establish sustainable, regionally relevant supply and evidence strategies.

Competitive dynamics where multinational scale and focused startup innovation converge, driving partnerships, platform strategies, and targeted clinical differentiation

The competitive landscape for implant technologies reflects a spectrum from established multinational device manufacturers to agile clinical-stage startups, creating a dynamic environment where scale, regulatory expertise, and focused innovation all matter. Large corporate players continue to leverage broad product portfolios, deep clinical networks, and extensive quality systems to support complex sales cycles and global regulatory submissions. These firms prioritize lifecycle management, modular platform strategies, and strategic partnerships that expand clinical indications and integrate digital health capabilities.

At the same time, smaller specialized companies and academic spinouts are driving breakthroughs in materials, sensing, and adaptive stimulation, often securing first-mover clinical differentiation in narrow indications. These innovators typically pursue targeted clinical proof points and strategic co-development or licensing arrangements to accelerate market entry. Investors and corporate development teams are focusing on collaborations that complement core strengths-such as pairing advanced biomaterials with established surgical instruments or attaching software-enabled analytics to proven implant platforms-to reduce time to clinical adoption and expand the perimeter of value for providers and patients. Across the competitive set, organizations that synchronize regulatory strategy, evidence generation, and commercial engagement will sustain differentiation and patient trust.

Practical strategic and operational measures companies should implement to enhance resilience, accelerate clinical adoption, and secure regulatory and payer alignment

Industry leaders must translate insight into practical steps that bolster resilience, accelerate adoption, and protect patient safety while preserving commercial viability. First, map critical supply chain nodes and qualify secondary suppliers for high-risk components, while implementing transparent cost and lead-time governance to reduce exposure to policy shifts and logistical disruption. Second, invest in clinical evidence generation that aligns with payer endpoints by designing pragmatic trials and real-world evidence programs that demonstrate improvements in functional outcomes, readmissions, and longitudinal device performance. Third, prioritize modularity and upgradeability in product design to extend clinical relevance and enable iterative improvements without wholesale replacement.

Additionally, integrate cybersecurity and software lifecycle management into device development from the earliest design phases, and establish clear pathways for post-market surveillance that leverage remote monitoring data where permitted. Pursue strategic alliances with health systems for co-developed value pathways and provider education programs to accelerate procedural adoption. Finally, cultivate policy engagement and regulatory intelligence capabilities to anticipate compliance changes and to align development timelines with evolving approval requirements, thereby reducing friction in market entry and scaling.

Integrated research approach combining clinical, regulatory, supply chain, and expert practitioner inputs to ensure comprehensive and validated findings

The research underpinning this analysis combined systematic review of regulatory documentation, peer-reviewed clinical literature, patents, and public device registries with targeted expert input from clinicians, procurement leaders, regulatory specialists, and manufacturing executives. Primary engagements included structured interviews and workshops with practicing surgeons across multiple specialties, quality and regulatory leaders within medical device firms, and supply chain managers responsible for implant logistics. Secondary research encompassed analysis of clinical trial registries, guidance documents issued by regulatory authorities, and device-specific post-market surveillance summaries to ensure a comprehensive view of safety and performance trends.

Data were triangulated by cross-referencing clinical outcomes, device technical specifications, and regulatory pathways to validate thematic findings. Limitations of the methodology include variability in public data completeness across regions and the proprietary nature of certain supplier contracts, which can constrain visibility into specific cost structures. To mitigate these constraints, qualitative weighting was applied where direct evidence was limited, and all primary inputs were anonymized and consented for use. Ethical standards were observed throughout the research process, with an emphasis on transparency and reproducibility of the analytic approach.

Synthesis of strategic priorities that connect device innovation, evidence generation, and operational resilience to realize durable clinical and system-level benefits

Biological implants are entering a phase where technological plurality and system-level considerations determine winner profiles and patient impact. The confluence of personalized materials, digital monitoring, and procedural innovation is reshaping the value equation from device-centric attributes to integrated care outcomes. Organizations that harmonize platform design, clinical evidence strategies, and adaptive manufacturing will not only navigate current policy and procurement pressures more effectively but will also unlock new avenues for sustainable adoption through demonstrable improvements in patient function and care efficiency.

Looking ahead, collaborators across industry, clinical practice, and policy will need to invest in interoperable ecosystems, transparent post-market evidence frameworks, and agile regulatory engagement to translate device innovation into measurable clinical benefits. The strategic priorities articulated in this summary-supply chain resilience, targeted evidence generation, and platform modularity-provide a pragmatic blueprint for leaders seeking to align innovation with real-world clinical and operational demands. Continued focus on patient-centric outcomes and responsible technology stewardship will be essential to maintaining public trust and ensuring that implantable technologies deliver durable health gains.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biological Implants Market, by Type

  • 8.1. Autografts
  • 8.2. Allografts
  • 8.3. Xenografts

9. Biological Implants Market, by Material

  • 9.1. Collagen-based
  • 9.2. Polymeric Materials
  • 9.3. Tissue-derived
  • 9.4. Hybrid/Bio-composite

10. Biological Implants Market, by Application

  • 10.1. Orthopedic Implants
  • 10.2. Cardiovascular Implants
  • 10.3. Dental Implants
  • 10.4. Craniofacial & Maxillofacial Implants

11. Biological Implants Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Biological Implants Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Biological Implants Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Biological Implants Market

15. China Biological Implants Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Abbott Laboratories
  • 16.6. AbbVie Inc.
  • 16.7. Alphatec Spine, Inc.
  • 16.8. Auto Tissue Berlin GmbH
  • 16.9. Baxter International, Inc.
  • 16.10. Becton, Dickinson and Company
  • 16.11. BioPolymer GmbH & Co. KG
  • 16.12. Boston Scientific Corporation
  • 16.13. Citagenix Inc.
  • 16.14. Conmed Corporation
  • 16.15. CryoLife, Inc.
  • 16.16. Edwards Lifesciences Corporation
  • 16.17. Globus Medical, Inc.
  • 16.18. Integra LifeSciences Corporation
  • 16.19. Johnson & Johnson
  • 16.20. Medical Device Business Services, Inc.
  • 16.21. Medtronic plc
  • 16.22. RTI Surgical, Inc.
  • 16.23. Sanara MedTech, Inc.
  • 16.24. Smith & Nephew plc
  • 16.25. Stryker Corporation
  • 16.26. Surgenex LLC
  • 16.27. TissueTech, Inc.
  • 16.28. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOLOGICAL IMPLANTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOLOGICAL IMPLANTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES BIOLOGICAL IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA BIOLOGICAL IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY AUTOGRAFTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY AUTOGRAFTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY AUTOGRAFTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ALLOGRAFTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ALLOGRAFTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ALLOGRAFTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY XENOGRAFTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY XENOGRAFTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY XENOGRAFTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY COLLAGEN-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY COLLAGEN-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY COLLAGEN-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY POLYMERIC MATERIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY POLYMERIC MATERIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY POLYMERIC MATERIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TISSUE-DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TISSUE-DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TISSUE-DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY HYBRID/BIO-COMPOSITE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY HYBRID/BIO-COMPOSITE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY HYBRID/BIO-COMPOSITE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DENTAL IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DENTAL IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DENTAL IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY CRANIOFACIAL & MAXILLOFACIAL IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY CRANIOFACIAL & MAXILLOFACIAL IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY CRANIOFACIAL & MAXILLOFACIAL IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. AMERICAS BIOLOGICAL IMPLANTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 40. AMERICAS BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 42. AMERICAS BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. NORTH AMERICA BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. LATIN AMERICA BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. LATIN AMERICA BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 51. EUROPE, MIDDLE EAST & AFRICA BIOLOGICAL IMPLANTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 59. MIDDLE EAST BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. MIDDLE EAST BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. MIDDLE EAST BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 62. MIDDLE EAST BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. AFRICA BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. AFRICA BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. AFRICA BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 66. AFRICA BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. ASEAN BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. ASEAN BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. ASEAN BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 75. ASEAN BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. GCC BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GCC BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. GCC BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 79. GCC BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPEAN UNION BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPEAN UNION BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPEAN UNION BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPEAN UNION BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. BRICS BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. BRICS BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. BRICS BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 87. BRICS BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. G7 BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. G7 BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. G7 BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 91. G7 BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. NATO BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. NATO BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. NATO BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 95. NATO BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. UNITED STATES BIOLOGICAL IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 98. UNITED STATES BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. UNITED STATES BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 100. UNITED STATES BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. CHINA BIOLOGICAL IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 102. CHINA BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. CHINA BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 104. CHINA BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)